Ensysce Biosciences (ENSC) Total Liabilities (2017 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Total Liabilities of $4.6 million for Q4 2025, up 106.0% year-over-year from $2.2 million in Q4 2024, and up 98.19% quarter-over-quarter from $2.3 million in Q3 2025.
Ensysce Biosciences (ENSC) Total Liabilities (2017 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Total Liabilities for 9 consecutive years, with $4.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities rose 106.0% year-over-year to $4.6 million; the TTM figure through Dec 2025 stood at $4.6 million (up 106.0% YoY), while the FY2025 annual figure was $4.6 million, up 106.0% from the prior year.
- Total Liabilities improved to $4.6 million in Q4 2025 per ENSC's latest filing, from $2.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $24.6 million in Q4 2021 and bottomed at $1.3 million in Q2 2024.
- Historically, Total Liabilities has averaged $6.3 million across 5 years, with a median of $3.7 million in 2021.
- Annual changes were most pronounced in 2021 — Total Liabilities jumped 250.56% — and 2023, when it slumped 85.99%.
- Ensysce Biosciences' Total Liabilities stood at $24.6 million in 2021, then slumped by 59.66% to $9.9 million in 2022, then plunged by 66.12% to $3.4 million in 2023, then sank by 34.0% to $2.2 million in 2024, then jumped by 106.0% to $4.6 million in 2025.
- Business Quant data shows ENSC's Total Liabilities at $4.6 million in Q4 2025, $2.3 million in Q3 2025, and $2.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | 4.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.57 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 2.51 Mn |
| Mar 31, 2025 | 1.89 Mn |
| Dec 31, 2024 | 2.22 Mn |
| Sep 30, 2024 | 2.80 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.65 Mn |
| Dec 31, 2023 | 3.36 Mn |
| Sep 30, 2023 | 2.06 Mn |
| Jun 30, 2023 | 2.56 Mn |
| Mar 31, 2023 | 4.07 Mn |
| Dec 31, 2022 | 9.91 Mn |
| Sep 30, 2022 | 14.71 Mn |
| Jun 30, 2022 | 8.75 Mn |
| Mar 31, 2022 | 11.26 Mn |
| Dec 31, 2021 | 24.58 Mn |
| Sep 30, 2021 | 10.10 Mn |
| Jun 30, 2021 | 4.03 Mn |
| Mar 31, 2021 | 11.09 Mn |